Patents by Inventor Stephen Squinto

Stephen Squinto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230303719
    Abstract: The disclosure provides humanized 3E10 antibodies and antigen binding fragments thereof. Compositions and methods of using the humanized 3E10 antibodies and antigen binding fragments thereof to deliver cargo are also disclosed.
    Type: Application
    Filed: March 2, 2023
    Publication date: September 28, 2023
    Inventors: Elias Quijano, Peter Glazer, Stephen Squinto, Dale Ludwig
  • Publication number: 20180289612
    Abstract: The invention relates to a composition for skin improvement or repair, comprising an extract of Boswellia frereana; a method of producing said composition; and a method of skin improvement or repair comprising use of said composition.
    Type: Application
    Filed: May 17, 2016
    Publication date: October 11, 2018
    Inventors: Stephen Squinto, Denise LePera
  • Publication number: 20070041972
    Abstract: Antibodies and/or fusion proteins contain a region that includes an IgG2-derived portion IgG4-derived portion.
    Type: Application
    Filed: May 28, 2004
    Publication date: February 22, 2007
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: Russell Rother, Dayang Wu, Stephen Squinto, Mark Evans, Susan McKnight
  • Patent number: 6916654
    Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: July 12, 2005
    Assignees: Oklahoma Medical Research Foundation, Yale University
    Inventors: Peter J. Sims, Alfred L. M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
  • Publication number: 20050118074
    Abstract: In a liquid handling system including a liquid handling substrate having a plurality of channels for conducting a liquid sample in said substrate, where the channels terminate in a plurality of exit ports in an outer surface of the substrate for transfer of a quantity of the liquid sample. The handling system also includes a liquid storage and dispensing substrate having a plurality of separable cartridges corresponding to the channels, with each cartridge terminating at a microelectro mechanical system (MEMS) comprising a laminate of glass, silicon and a piezoelectric substance. The handling system further includes a liquid detecting system comprising a light emitting diode and a photo-detector, where each channel includes a reservoir in communication with a corresponding cartridge creating an interface therebetween.
    Type: Application
    Filed: December 28, 2004
    Publication date: June 2, 2005
    Applicant: BioProcessors Corp.
    Inventors: Allyn Hubbard, Samesh Kale, Scott Rollins, Jeremy Springhorn, Stephen Squinto, Prasad Akkapeddi
  • Patent number: 6100443
    Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 8, 2000
    Assignees: Oklahoma Medical Research Foundation, Yale University
    Inventors: Peter J. Sims, Alfred L. M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto
  • Patent number: 5705732
    Abstract: Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: January 6, 1998
    Assignees: Oklahoma Medical Research Foundation, Yale University
    Inventors: Peter J. Sims, Alfred L.M. Bothwell, Eileen A. Elliot, Richard A. Flavell, Joseph Madri, Scott Rollins, Leonard Bell, Stephen Squinto